抗辐射性
辐射敏感性
突变体
癌症研究
DNA损伤
放射治疗
体内
突变
体外
生物
抑制器
癌症
细胞培养
突变
细胞
A549电池
化学
抑制因子
PARP1
癌细胞
DNA
细胞毒性
聚ADP核糖聚合酶
作者
Mengjia Wu,Chaoyuan Pu,Wanxuan Weng,Fengmin Yin,Lei Zhang,Chenggang Xu,Mingjian Li,Chuanhui Cao,Wei Hu
标识
DOI:10.1038/s41698-026-01526-7
摘要
Radiotherapy is a crucial therapeutic approach for the management of non-small cell lung cancer (NSCLC). Nevertheless, the radioresistance of NSCLC, particularly in cases involving the gain-of-function mutant p53, substantially limits its efficacy. According to recent research, mutant p53 R273H can recruit poly (ADP-ribose) polymerase (PARP)-1 on replicating DNA to promote tumor survival. Whether mutant p53 R273H-mediated radioresistance is related to the interaction between mutant p53 R273H and PARP1, and if PARP1 inhibitors (PARPi) can increase the radiosensitivity of mutant p53 R273H-expressing tumors have not been explored. Through in vitro and in vivo experiments, we determined that mutant p53 R273H promotes radioresistance in NSCLC by partially inhibiting ferroptosis through the SLC7A11/GSH/GPX4 axis, independently of PARP1, whereas FZ counteracts this effect by partially blocking the same axis to promote ferroptosis, presenting a potential novel strategy for treating NSCLC patients with gain-of-function mutant p53 R273H.
科研通智能强力驱动
Strongly Powered by AbleSci AI